EP0380558A4 - Liposomal nucleoside analogues for treating aids - Google Patents

Liposomal nucleoside analogues for treating aids

Info

Publication number
EP0380558A4
EP0380558A4 EP19880908811 EP88908811A EP0380558A4 EP 0380558 A4 EP0380558 A4 EP 0380558A4 EP 19880908811 EP19880908811 EP 19880908811 EP 88908811 A EP88908811 A EP 88908811A EP 0380558 A4 EP0380558 A4 EP 0380558A4
Authority
EP
European Patent Office
Prior art keywords
liposomal
nucleoside analogues
treating aids
aids
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19880908811
Other languages
English (en)
Other versions
EP0380558A1 (de
Inventor
Karl Y. Hostetler
Douglas D. Richman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of EP0380558A1 publication Critical patent/EP0380558A1/de
Publication of EP0380558A4 publication Critical patent/EP0380558A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
EP19880908811 1987-09-22 1988-09-19 Liposomal nucleoside analogues for treating aids Ceased EP0380558A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9975587A 1987-09-22 1987-09-22
US99755 1987-09-22

Publications (2)

Publication Number Publication Date
EP0380558A1 EP0380558A1 (de) 1990-08-08
EP0380558A4 true EP0380558A4 (en) 1991-07-31

Family

ID=22276457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880908811 Ceased EP0380558A4 (en) 1987-09-22 1988-09-19 Liposomal nucleoside analogues for treating aids

Country Status (4)

Country Link
EP (1) EP0380558A4 (de)
JP (1) JPH03501253A (de)
AU (1) AU2526188A (de)
WO (1) WO1989002733A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
ZA902710B (en) * 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
DE3916595A1 (de) * 1989-05-22 1990-11-29 Boehringer Mannheim Gmbh Verfahren zur nichtradioaktiven messung der nucleinsaeuresynthese in eukaryontischen zellen
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
JPH04505929A (ja) * 1989-12-08 1992-10-15 シティ・オブ・ホープ ヒトの抗癌剤の耐性の回避
FR2683721B1 (fr) * 1991-11-15 1995-06-09 Inocosm Laboratoires Composition lipidique polaire permettant de vehiculer un agent actif et/ou de le faire penetrer dans une cellule cible.
US5817646A (en) * 1991-11-15 1998-10-06 Laboratoires Inocosm Polar lipid composition of plant origin
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT2415776T (pt) 1998-08-10 2016-07-07 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
DE69939604D1 (de) 1998-11-02 2008-10-30 Gilead Sciences Inc Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
ATE281179T1 (de) * 1999-08-13 2004-11-15 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
CA2405502A1 (en) 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (de) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
WO2002032920A2 (en) 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
CN102942563A (zh) 2001-03-01 2013-02-27 基利得科学公司 顺-ftc的多晶型物及其它晶型
EP1435974A4 (de) 2001-09-28 2006-09-06 Idenix Cayman Ltd Verfahren und zusamemnsetzungen zur behandlung des hepatitis-c-virus mit 4'-modifizierten nucleosiden
JP2005523249A (ja) 2002-01-09 2005-08-04 エンズレル インコーポレイテッド 多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
EP1572095B1 (de) 2002-09-13 2015-06-10 Novartis AG Beta-l-2'-desoxynucleoside zur verwendung in der behandlung von resistenten hbv-stämmen
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114577A1 (de) * 1983-01-21 1984-08-01 MAGIS FARMACEUTICI S.p.A. Pharmazeutische Zusammenstellung
EP0152379A2 (de) * 1984-02-15 1985-08-21 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
EP0216511A2 (de) * 1985-08-26 1987-04-01 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Hemmung der In-vitro-Infektivität und des zytopathischen Effektes von HTLV-III/LAV durch 2'3'-Dideoxycytidin
EP0267050A2 (de) * 1986-11-06 1988-05-11 Research Development Foundation Aerosole, die Liposome beinhalten, und Verfahren zu deren Herstellung.
NL8700089A (nl) * 1987-01-15 1988-08-01 Stichting Rega V Z W Therapeutische toepassing van dideoxythymidine en dideoxythymidineen.
WO1988005657A1 (en) * 1987-01-28 1988-08-11 Chu Chung K 3'-azido-2',3'-dideoxyuridine anti-retroviral composition
EP0286418A1 (de) * 1987-04-10 1988-10-12 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Anti-retrovirale Stoffe und dazugehörige Verabreichungssysteme

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
ZA833446B (en) * 1982-05-28 1984-02-29 Solco Basel Ag Process for the preparation of cell-and tissue-regenerating substances
US4704357A (en) * 1985-09-30 1987-11-03 United States Of America As Represented By The Department Of Health And Human Services Immortalized T-lymphocyte cell line for testing HTLV-III inactivation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114577A1 (de) * 1983-01-21 1984-08-01 MAGIS FARMACEUTICI S.p.A. Pharmazeutische Zusammenstellung
EP0152379A2 (de) * 1984-02-15 1985-08-21 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
EP0216511A2 (de) * 1985-08-26 1987-04-01 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Hemmung der In-vitro-Infektivität und des zytopathischen Effektes von HTLV-III/LAV durch 2'3'-Dideoxycytidin
EP0267050A2 (de) * 1986-11-06 1988-05-11 Research Development Foundation Aerosole, die Liposome beinhalten, und Verfahren zu deren Herstellung.
NL8700089A (nl) * 1987-01-15 1988-08-01 Stichting Rega V Z W Therapeutische toepassing van dideoxythymidine en dideoxythymidineen.
WO1988005657A1 (en) * 1987-01-28 1988-08-11 Chu Chung K 3'-azido-2',3'-dideoxyuridine anti-retroviral composition
EP0286418A1 (de) * 1987-04-10 1988-10-12 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Anti-retrovirale Stoffe und dazugehörige Verabreichungssysteme

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8902733A1 *

Also Published As

Publication number Publication date
WO1989002733A1 (en) 1989-04-06
AU2526188A (en) 1989-04-18
JPH03501253A (ja) 1991-03-22
EP0380558A1 (de) 1990-08-08

Similar Documents

Publication Publication Date Title
EP0380558A4 (en) Liposomal nucleoside analogues for treating aids
EP0301414B1 (en) Surface active hydroxysulfonates
JPS6468373A (en) Therapeutical nucleoside
HU210815A9 (en) Therapeutic nucleosides
EP0375726A4 (en) Melatonin analogues
EP0286425A3 (en) Therapeutic nucleosides
ZA876673B (en) Nucleoside analogues
PH25577A (en) Purine derivatives
GB8827337D0 (en) Nucleoside analogues
GB8706176D0 (en) Therapeutic nucleosides
EP0287215A3 (en) Therapeutic nucleosides
GB8614733D0 (en) Aids treatment
ZA883830B (en) Therapeutic nucleosides
GB8725466D0 (en) Purine derivatives
IE872385L (en) Nucleoside analogues
GB8805832D0 (en) Surface treatment
IE870520L (en) Isohexide nucleoside
GB8713293D0 (en) Massaging aid
GB8725179D0 (en) Aids for disabled
GB8719401D0 (en) Immobilization of fungal beta-galactosidase
GB8702795D0 (en) Bath aids
GB8919507D0 (en) Nucleoside analogues
GB8904162D0 (en) Nucleoside analogues
IE871695L (en) Azabicycloalka(e)ne derivatives
IE883323L (en) Therapeutic nucleoside analogues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

A4 Supplementary search report drawn up and despatched

Effective date: 19910610

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19930513